Galenica Ltd.

Latest Results (16.03.2026):

This summary covers Galenica Ltd.'s fourth quarter of 2024 (full‑year 2024 results, reporting period 1 January–31 December 2024). Galenica Ltd. and the Galenica Group reported consolidated net sales of CHF 3,921.1 million (up 4.7% vs. 2023) and adjusted EBIT of CHF 211.0 million (up 10.3%). Adjusted profit from continuing operations was CHF 183.2 million (+13.4%). The Board proposes a gross dividend of CHF 2.30 per share. Key balance‑sheet and cash metrics showed strengthened equity (CHF 1,551.8 million) and positive free cash flow (CHF 61.0 million), while adjusted net debt rose to CHF 424.1 million.

Top‑line and growth

Consolidated net sales: CHF 3,921.1m, +4.7% year‑on‑year. Products & Care sales CHF 1,700.2m (+3.9%); Logistics & IT reported CHF 3,241.4m (+5.3%) (segment reporting excludes Group Services/Eliminations).

Profitability

EBIT (reported) CHF 214.4m (+7.6%); EBIT adjusted CHF 211.0m (+10.3%), representing an adjusted EBIT margin of 5.4% on group sales. Products & Care adjusted EBIT CHF 157.3m (margin ~9.2%); Logistics & IT adjusted EBIT CHF 56.8m (margin ~1.8%), with Logistics & IT showing strong relative EBIT improvement (+34.2%).

Net profit and per‑share metrics

Profit from continuing operations CHF 183.7m (+10.9%); adjusted profit CHF 183.2m (+13.4%). Adjusted earnings per share ~CHF 3.66. Share price at reporting date CHF 74.35, market capitalisation ~CHF 3,704.6m. Board proposes gross dividend CHF 2.30/share (up 4.5%), dividend yield ~3.1%.

Cash flow and balance sheet

Free cash flow CHF 61.0m (+23.7%). Cash flow from operating activities (adjusted) CHF 212.1m (+22.3%). Investments (PP&E & intangibles) CHF 72.8m (-7.7%). Shareholders' equity CHF 1,551.8m (+5.2%); adjusted net debt CHF 424.1m (+17.1%), gearing adjusted ~27.0%.

Operational and commercial highlights

Customer/operations: ~193,000 consultations and healthcare services delivered (+39% YoY); pharmacies grew organically (+2.7%) and expanded via acquisitions/openings (12 acquired, 2 opened). Generic substitution rate in pharmacies ~79.2%. Verfora and export growth supported by Perskindol® and other product deliveries.

Digital & safety metrics; sustainability progress

HCI Solutions performed strongly: ~369 million clinical decision support (CDS) checks in 2024 (+33%), supporting patient safety. Alloga earned EcoVadis recognition; joint venture Health Supply (with Planzer) progressed according to plan. Company highlights continued integration of digital platforms, a new Data & AI Governance Board and sustainability reporting aligned with TCFD and GRI.